Vaccinogen Inc. | Balance Sheet

Fiscal year is January-December. All values USD Thousands.
2011
2012
2013
2014
Cash & Short Term Investments
277.20
155.90
117.50
3,080.50
Inventories
105.60
102.20
100.20
99.30
Other Current Assets
75.40
140.30
115.50
2,910.50
Total Current Assets
458.20
398.40
333.20
6,090.20
Net Property, Plant & Equipment
162.60
107.50
198.80
393.00
Intangible Assets
76,132.10
69,428.80
62,725.60
56,022.30
Other Assets
-
1,301.50
-
8,575.80
Total Assets
76,752.90
71,236.20
63,257.50
71,081.40
ST Debt & Current Portion LT Debt
4,975.40
5,300.00
4,831.20
-
Accounts Payable
1,058.00
2,021.00
3,357.30
-
Other Current Liabilities
1,114.00
4,575.60
14,460.50
5,535.10
Total Current Liabilities
7,147.30
11,896.60
22,649.00
5,535.10
Long-Term Debt
-
-
-
3,000.00
Other Liabilities
-
-
-
9,670.70
Total Liabilities
7,147.30
11,896.60
22,649.00
18,205.80
Common Equity (Total)
49,522.90
59,339.60
40,608.50
52,875.50
Total Shareholders' Equity
69,605.60
59,339.60
40,608.50
52,875.50
Total Equity
69,605.60
59,339.60
40,608.50
52,875.50
Liabilities & Shareholders' Equity
76,752.90
71,236.20
63,257.50
71,081.40
Preferred Stock (Carrying Value)
119,128.50
-
-
-

About Vaccinogen

View Profile
Address
949 Fell Street
Baltimore Maryland 21231
United States
Employees -
Website http://www.vaccinogeninc.com
Updated 09/14/2018
Vaccinogen, Inc. is an immunotherapy company. The company engages in the development and commercialization of vaccines and immunotherapeutic products for cancer. Its primary product, OncoVAX is a vaccine for post-surgical treatment of stage II colon cancer.